Whitehawk Therapeutics Inc(WHWK)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• Whitehawk Therapeutics faces a precarious outlook as its revenue stream has completely evaporated, dropping to zero by 2025Q4, while R&D expenditures remain unsustainably high at $19.0 million for the same period.
• The company's reliance on non-recurring milestone payments has failed to establish a viable commercial pipeline, leaving shareholders exposed to significant dilution or potential liquidation.
• Investors should monitor the rapid depletion of cash reserves, which fell from $227.6 million in 2025Q1 to $37.6 million by 2025Q4, as the firm lacks the tangible asset base to support its current valuation.